Neuro-Oncology · 2010 · 66 citations · 18 references
MedicineMolecular BiologyOncologyEpigeneticsMolecular OncologyNeuro-oncologyBrain TumorsCancer BiomarkersDna MethylationDna Methylation ProfilingEpigenetic BiomarkersGlioblastomaDna Methylation BiomarkersDna MethyltransferasesFisher’s Exact TestGlioblastoma EpigeneticsMethylation BiomarkersMethylation-specific AmplificationProtein Expression BiomarkersTemozolomide Therapy
Molecular alterations in glioblastoma have the potential to guide treatment. Here, we explore the relationship between temozolomide (TMZ) response and O(6)-methylguanine DNA methyltransferase (MGMT) status in brain tumor initiating cells (BTICs). Methylation, expression, and sensitivity were assessed in 20 lines; associations were evaluated by Fisher's exact test. Some BTICs were sensitive. Sensitivity to TMZ was only associated with protein expression (P = .001). There were atypical BTICs including TMZ-resistant lines in which the methylation-specific PCR reaction revealed both methylated and unmethylated bands. BTICs are not uniformly resistant to TMZ; some are sensitive. MGMT status does not predict TMZ response with high precision.
18
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp, Warren Mason, Martin J. van den Bent et al. · New England Journal of Medicine · 2005 · 21.6K citations · Full text
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma
Monika E. Hegi, Annie‐Claire Diserens, Thierry Gorlia et al. · New England Journal of Medicine · 2005 · 7.3K citations · Full text